Exelixis, Inc. v. Azurity Pharmaceuticals, Inc. et al
| Delaware District Court | |
| Judge: | Richard G Andrews |
| Case #: | 1:25-cv-00478 |
| Nature of Suit | 835 Property Rights - Patent – Abbreviated New Drug Application |
| Cause | 35:271 Patent Infringement |
| Case Filed: | Apr 18, 2025 |
| Last checked: Tuesday Apr 22, 2025 1:08 AM EDT |
|
Defendant
Azurity Pharmaceuticals India LLP
|
|
|
Defendant
Azurity Pharmaceuticals, Inc.
|
|
|
Defendant
Slayback Pharma India LLP
|
|
|
Defendant
Slayback Pharma LLC
|
|
|
Plaintiff
Exelixis, Inc.
|
Represented By
|
| Docket last updated: 11 hours ago |
| Thursday, April 24, 2025 | ||
| 7 | 7
20
pgs
cmp
Complaint - Amended
Thu 04/24 5:00 PM
First AMENDED COMPLAINT For Patent Infringement against Azurity Pharmaceuticals India LLP, Azurity Pharmaceuticals, Inc., Slayback Pharma India LLP, Slayback Pharma LLC- filed by Exelixis, Inc..(Raucci, Anthony) |
|
|
Att: 1
Exhibit A-F
|
||
| Wednesday, April 23, 2025 | ||
|
utility
Case Assigned/Reassigned
Wed 04/23 8:28 AM
Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (alb) |
||
| Monday, April 21, 2025 | ||
| 6 | 6
service
Summons Issued
Mon 04/21 9:04 AM
Summons Issued as to Azurity Pharmaceuticals India LLP on 4/21/2025; Azurity Pharmaceuticals, Inc. on 4/21/2025; Slayback Pharma India LLP on 4/21/2025; Slayback Pharma LLC on 4/21/2025.(cdd) |
|
|
Att: 1
Summons Issued,
|
||
|
Att: 2
Summons Issued,
|
||
|
Att: 3
Summons Issued
|
||
| Friday, April 18, 2025 | ||
| 5 | 5
misc
Disclosure Statement - Rule 7.1
Mon 04/21 9:02 AM
Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Exelixis, Inc. (cdd) |
|
| 4 | 4
misc
Patent/Trademark Report to Commissioner of Patents
Mon 04/21 9:00 AM
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,877,776 B2; 11,091,439 B2; 11,091,440 B2; 11,098,015 B2 ; 12,128,039 B2; 11,298,349 B2. (cdd) |
|
| 3 | 3
misc
ANDA Form
Mon 04/21 8:58 AM
Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 3/6/2025. Date of Expiration of Patent: U.S. Patent No. 8,877,776 expires on 10/8/2030; U.S. Patent Nos. 11,091,439, 11,091,440, and 11,098,015 expire on 1/15/2030; U.S. Patent Nos. 11,298,349 and 12,128,039 expires on 2/10/2032. Thirty Month Stay Deadline: 9/6/2027. (cdd) |
|
| 2 | 2
misc
Magistrate Consent Forms
Mon 04/21 8:43 AM
Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cdd) |
|
| 1 | 1
20
pgs
cmp
Complaint
Mon 04/21 8:42 AM
COMPLAINT for ANDA/PATENT INFRINGEMENT filed with No Jury Demand against Azurity Pharmaceuticals India LLP, Azurity Pharmaceuticals, Inc., Slayback Pharma India LLP, Slayback Pharma LLC ( Filing fee $ 405, receipt number ADEDC-4665390.) - filed by Exelixis, Inc.(cdd) |
|
|
Att: 1
Exhibit A-F,
|
||
|
Att: 2
Civil Cover Sheet
|
||